NEWS

2020

Apr 22 2020 AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon

2019

Sep 27 2019 AMIDEBIO awarded $1.56M NIH Phase II SBIR

2018

Nov 16 2018 David Brunel takes over Chairmanship at AMIDEBIO
Sep 3 2018 Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AMIDEBIO
May 16 2018 Diabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AMIDEBIO

2017

Nov 14 2017 Dr. Charles A. Stanley joins AmideBio’s Scientific Advisory Board
Nov 12 2017 Dr. David L. Snitman joins AmideBio’s Business Advisory Board
Nov 7 2017 AmideBio Closes $764,000 Preferred Equity Financing
Sep 24 2017 AmideBio awarded $338,387 NIH SBIR grant for congenital hyperinsulinism treatment
Jul 1 2017 AmideBio granted European patent protection for peptide production platform technology
Jun 28 2017 AmideBio CTO Dr. Michael Stowell will present at the 2017 International Congenital Hyperinsulinism Conference

2016

Jun 20 2016 ADA poster available for download

Jun 6 2016 AmideBio CTO Dr. Michael Stowell to present a poster at the 76th american diabetes association meeting

2015

Oct 22 2015 AmideBio Presents at 2015 Peptide Therapeutics Foundation Symposium, La Jolla, CA

Oct 17 2015 AmideBio CTO Dr. Michael Stowell’s structural work on a potential novel target for Alzheimer’s published

May 12 2015 AmideBio Announces Availability of BioPure™ Hg1 Toxin for Research

2014

Aug 21 2014 AmideBio Obtains Core Patent for Peptide Production Platform Technology

Apr 15 2014 AmideBio Announces Addition of Mr. Vincent P. Mihalik to Board of Directors

2013

Nov 13 2013 AmideBio Announces Addition of Mr. Daniel M. Bradbury to Business Advisory Board

Oct 24 2013 AmideBio Announces Addition of Dr. Conrad Hummel as Director of Business Development

Aug 25 2013 AmideBio Selected to Present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference

Jun 20 2013 AmideBio Announces Availability of BioPure™ Amyloid-beta for Alzheimer’s Research

Jun 10 2013 AmideBio Announces Addition of Dr. Gilad S. Gordon to Scientific Advisory Board

2012

Dec 13 2012 AmideBio Announces Addition of Dr. John P. Mayer to Scientific Advisory Board

Oct 4 2012 AmideBio to present at 24th Annual Colorado Capital Conference on October 9, 2012

Aug 9 2012 AmideBio Announces Addition of Dr. William S. Marshall to Business Advisory Board

Jun 8 2012 AmideBio Announces Addition of Dr. Robert S. Hodges to Scientific Advisory Board

Apr 3 2012 AmideBio Announces Addition of Dr. John C. Hutton to Scientific Advisory Board

Mar 9 2012 AmideBio Announces Addition of Michael Carruthers to Business Advisory Board

Feb 20 2012 Dr. Michael Stowell, CTO of AmideBio, to Speak at TIDES Conference in May 2012

2011

Aug 17 2011 AmideBio elects David. L. Barker, Ph.D., to its Board of Directors

Jun 16 2011 AmideBio Moves to New Location

May 10 2011 AmideBio Closes $575,000 Preferred Equity Financing

Apr 4 2011 AmideBio Announces Addition of Thomas Keuer to Business Advisory Board

Feb 17 2011 AmideBio Licenses University of Colorado Alzheimer’s Treatment

Feb 15 2011 AmideBio CEO Misha Plam Receives SBA Award for Exceptional Innovation

Dec 31 2010 AmideBio to Present at TIDES Conference on May 24, 2011

2010

Sep 9 2010 AmideBio Selected as a Finalist in the BioWest Venture Showcase Competition

Jul 1 2010 AmideBio and Novus Biologicals Sign Distribution Agreement

Apr 14 2010 AmideBio Expands Alzheimer’s Disease Partnership with the University of Colorado

Jan 26 2010 AmideBio Closes Seed Financing

Jan 11 2010 AmideBio Licenses Peptide Manufacturing Technology from the University of Colorado

COMPANY NEWS

AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon2020-04-22 - 17:35
AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon analog (ABG-023) for the treatment of congenital hyperinsulinism (CHI). ABG-023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon – […]
AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33
AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the […]
David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47
AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of the Board, replacing Misha Plam. Dr. Plam, a founder of AmideBio who retired recently as President and CEO, is now Chairman Emeritus. Read the full press release.